文献速递消化系统肿瘤

西妥昔单抗与维莫非尼联合FOLFIRI(5-氟尿嘧啶/亚叶酸钙/伊立替康)治疗BRAF V600E突变晚期结直肠癌(IMPROVEMENT):一项开放标签、单臂、II期试验

Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial.
PubMed 文献 · Eur J Cancer · 2022-01-21

该研究为研究者发起的开放标签单臂II期试验,纳入21例BRAF V600E突变晚期结直肠癌患者,接受维莫非尼和西妥昔单抗联合FOLFIRI方案。意向治疗人群客观缓解率为81.0%(17/21;95%CI 57.4-93.7),中位无进展生存期9.7个月,中位总生存期15.4个月。结论认为该方案可安全联合,显示出有前景的抗肿瘤活性和可耐受毒性,值得进一步开展III期随机研究。

要点

  • 意向治疗人群客观缓解率81.0%(17/21;95%CI 57.4-93.7),符合方案人群85.0%(17/20;95%CI 61.0-96.0)。
  • 中位无进展生存期9.7个月(95%CI 6.3-10.9),中位总生存期15.4个月(95%CI 8.5-15.4)。
  • 最常见3-4级不良事件为中性粒细胞减少(8/21)、贫血(3/21)和皮疹(3/21)。

核心结论

  • 维莫非尼和西妥昔单抗可安全地与FOLFIRI方案联合,在BRAF V600E突变晚期结直肠癌患者中显示出有前景的抗肿瘤活性和可耐受的毒性。
  • 该方案值得进一步开展III期临床试验的随机研究。

研究设计与样本

  • 研究者发起的开放标签、单臂、II期试验,纳入BRAF V600E突变晚期结直肠癌患者。
  • 患者接受FOLFIRI联合维莫非尼和西妥昔单抗治疗。
  • 主要终点为客观缓解率,次要终点包括疾病控制率、无进展生存期、总生存期和安全性。
  • 2018年1月12日至2021年6月18日期间筛查27例患者,其中21例入组。
  • 试验注册于ClinicalTrials.gov,注册号NCT03727763。

主要发现

  • 意向治疗人群客观缓解率为81.0%(17/21;95%CI 57.4-93.7),符合方案人群为85.0%(17/20;95%CI 61.0-96.0)。
  • 2例患者达到完全缓解,15例患者达到部分缓解。
  • 整个队列中位无进展生存期为9.7个月(95%CI 6.3-10.9),所有患者中位总生存期为15.4个月(95%CI 8.5-15.4)。
  • 最常见3-4级不良事件为中性粒细胞减少(8/21)、贫血(3/21)和皮疹(3/21)。

关键数值与推荐

  • 客观缓解率:意向治疗人群81.0%(17/21;95%CI 57.4-93.7),符合方案人群85.0%(17/20;95%CI 61.0-96.0)。
  • 中位无进展生存期9.7个月(95%CI 6.3-10.9),中位总生存期15.4个月(95%CI 8.5-15.4)。
  • 3-4级不良事件:中性粒细胞减少8/21、贫血3/21、皮疹3/21。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current therapeutic regimens for patients with v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E-mutated colorectal cancer show unsatisfactory efficacy. To improve outcomes in this area, we assessed the safety and efficacy of a new protocol using vemurafenib and cetuximab combined with FOLFIRI (5-fluorouracil/leucovorin/irinotecan) in patients with BRAF V600E-mutated colorectal cancer. METHODS AND MATERIALS: This was an investigator-initiated, open-label, single-arm, phase II trial conducted in patients with BRAF V600E-mutated advanced colorectal cancer. Patients were eligible to receive FOLFIRI combined with vemurafenib and cetuximab. The primary end-point was the objective response rate, and the secondary end-points included disease control rate, progression-free survival, overall survival and safety. This trial is registered with ClinicalTrials.gov, NCT03727763. RESULTS: Between 12th January 2018, and 18th June 2021, we screened 27 patients, 21 of which were enrolled in this study. Efficacy analysis showed that objective response rates were 81.0% (17/21; 95% confidence interval [CI] 57.4-93.7) in the intention-to-treat population and 85.0% (17/20, 95%CI 61.0-96.0) in the per-protocol population; two patients achieved complete response, and 15 patients achieved a partial response. In the entire cohort, the median progression-free survival was 9.7 months (95%CI 6.3-10.9), and the median overall survival for all patients was 15.4 months (95%CI 8.5-15.4). The most common adverse events (grade 3 to 4) were neutropenia (8/21), anaemia (3/21) and skin rash (3/21). CONCLUSION: Vemurafenib and cetuximab can be safely combined with the FOLFIRI regimen, showing promising antitumour activity and tolerable toxicity in patients with BRAF V600E-mutated advanced colorectal cancer. This regimen warrants a further randomised study in phase III clinical trials.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Wang Z, Qin BD, Ye CY, et al. Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial. Eur J Cancer. 2022. PMID: 35074651. doi:10.1016/j.ejca.2021.12.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。